The Balance of Safety and Efficacy: Understanding Target Antigen Density in Cancer Treatments with the IndEx-2 Inducible Cell Line Platform

Receptor expression levels is a critical factor influencing the efficacy and safety of targeted immuno-oncology therapeutics, including immune cell engagers and CAR-T therapies. However, there is a notable paucity of in vitro systems designed to elucidate the relationship between target antigen density and the performance metrics of these therapeutic modalities.

In this webinar, Dr. Timothy London, Scientific Director of Molecular Biology at Antibody Analytics will present IndEx-2, an advanced in vitro cell-based platform engineered to modulate the expression of one or two target antigens across a range of biologically relevant levels. By integrating IndEx-2 with tools such as the Agilent xCELLigence Real Time Cell Analyzer (RTCA) and NovoCyte Flow Cytometer, and cytokine release measurement protocols, the antigen density thresholds required for the activation of potential immunotherapeutic candidates can be determined. Importantly, this comprehensive approach caters to a diverse array of functional readouts, spanning from cytotoxic responses to immune cell activation.

Key learning objectives

• Understand why antigen density is important in the development of cancer immunotherapies
• Explore how the IndEx-2 in vitro system can be combined with the xCELLigence Real Time Cell Analyzer (RTCA) and NovoCyte Flow Cytometer to determine receptor thresholds of activation
• Discover the power of the customizable IndEx-2 in vitro cell line system for modeling physiological and pathological target expression levels
• Learn how the IndEx-2 bioassays powered by kinetic cytotoxicity measurements can be used to identify lead candidates with desired characteristics

Who should attend?

• Therapeutic drug developers with pre-clinical development programs of cell therapies, immune cell engagers, particularly T cell engagers, engineered cell therapies, antibody drug conjugates, monoclonal antibodies and bispecific antibodies.
• Those wishing to better understand the potential of on target, off tumor (OTOT) effects of their targeted drug candidates in a pre-clinical, in vitro setting.
• Developers wishing to develop a detailed activity profile of their molecules and select clinical leads based on these attributes.

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.